U.S. Markets closed

AstraZeneca PLC (AZN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
29.12+0.04 (+0.14%)
At close: 4:02PM EDT
People also watch
GSKNVSSNYLLYBMY
  • Y
    YouBetcha
    YouBetcha
    Any thoughts regarding Benralizumab and approval and whether or not it will bring the share price up?
  • R
    Rigvze
    Rigvze
    Fundamental growth and profitability are looking good. Higher rating at stockFA. Expected to pick up momentum.
  • A
    Al on CC
    Al on CC
    What happened to Dividend? It was 1.90 a few days ago. Now .90. This site is very inaccurate.
  • J
    Joseph
    Joseph

    I think that the following news are interesting
    Food and Drug Administration (FDA) had agreed to speed up the process needed for its new lung cancer drug Imfinzi: http://www.proactiveinvestors.co.uk/companies/news/181726/astrazeneca-bolstered-by-fda-news-on-lung-cancer-drug-imfinzi-181726.html
    Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31585-4/fulltext
    Although neither of them will mean definite FDA approval they look promising.

    AstraZeneca bolstered by FDA news on lung cancer drug Imfinzi
    AstraZeneca (LON:AZN) - The regulator has granted breakthrough therapy designation for Imfinzi
    www.proactiveinvestors.co.uk
  • M
    Mike
    Mike

    https://seekingalpha.com/article/4100024-astrazeneca-time-expand-operation

    AstraZeneca, Time To Expand The Operation
    FDA expanded label for Lynparza should help treat a wider ovarian cancer patient population. Positive phase 3 data served as the basis for the expanded approval
    seekingalpha.com
  • n
    nito
    nito
    No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry
    The quest to improve vaccination efforts in developing nations may yield huge side benefits to the industrialized world; an end to needle injections.
    www.businesswire.com
  • C
    Carl
    Carl
    AZN reportedly goes ex-dividend next week. I believe the date is 8/9.
  • C
    Carl
    Carl
    Up almost 1% in pre-market. Looks like buyers are coming back and paying up. Any speculation of a possible deal will make this baby pop, and that appears to be behind the buying interest.
  • C
    Carl
    Carl
    Looks like $30 is the new base. Once speculation starts about who might have an interest in buying AZN, I expect the stock will move up a couple of bucks. The upcoming generous dividend makes it easy to hold and wait, especially if you bought on the recent drop.
  • C
    Carl
    Carl
    AZN's drop has made it more attractive as a buyout play. Next week's dividend is another positive reason to be buying in here. Just saw an article saying PFE's less than stellar earnings show a need to do a deal. If not PFE, could be another large pharma come a knockin'.
  • j
    junpeng
    junpeng
    It will go up
  • A
    Athra Jatt
    Athra Jatt
    AZN should give us a bit of a pop today.
  • H
    Hey Hey Hey
    Hey Hey Hey
    For as much as I want a buyout, I don't think it will happen with Soriot and the current board. Soriot has to go before he destroys anymore shareholder value. The media has to stop to referring to the PFE offer #$%$ GBP/share, that minimizes the damage Soriot has already inflicted on the shareholders including that homer Woodford. The PFE offer was $116-$120 Billion. Soriot cost the shareholders $45+ Billion dollars. None of the promises from his forked tongue will come to fruition. All we can hope for is if an activist shareholder can force the company to put itself up for sale.. I can't believe any of the large shareholders can just sit passively as Soriot continues to sell off the family jewels to hit his bonus.
  • J
    Joe
    Joe
    Benralizumab has an FDA action date during Q4 2017 and AstraZeneca are preparing to launch in the US in the beginning of 2018 .
  • s
    smok
    smok
    I bought some AZN because they make great meds. So thankful.
  • j
    jaroslav
    jaroslav
    up to 34
  • j
    junpeng
    junpeng
    AH traded @$31.5, was it for real?
  • H
    Hey Hey Hey
    Hey Hey Hey
    I expect Soriot to leave for Teva now that the bad news is out since he can't be accused of acting on non-public info anymore. If the board has any sense of fairness to the shareholders, this company should be put up for sale.
  • D
    Dana
    Dana
    The PFE guys must be happy that they did not make a huge mistake buying AZN.
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.